

July 27, 2009

Whom It May Concern

KYORIN Co., Ltd.
5, Kanda Surugadai 2-chome,
Chiyoda-ku, Tokyo
Securities code; 4569, TSE 1st Section

Grant of Marketing Right to Senju Pharmaceutical
on Gatifloxacin Ophthalmic Solution in China

KYORIN Co., Ltd. announces that its wholly owned subsidiary of KYORIN Pharmaceutical Co., Ltd. ("Kyorin") (Head office: Tokyo, President: Keiji Hirai, Ph.D.) today signed a License Agreement with Senju Pharmaceutical Co., Ltd. ("Senju") (Head office: Osaka, President: Yukoh Yoshida), concerning the grant of an exclusive marketing right to Senju on Gatifloxacin ophthalmic solution for China. Gatifloxacin is a broad spectrum synthetic antibacterial agent originated by Kyorin.

Kyorin and Senju entered into a licensing arrangement on this product for Japan territory in August 1997, and Senju is currently manufacturing and marketing it in Japan. Senju places the expansion of its Chinese business as one of its business challenges and will promote it by introducing this product into the Chinese market. Gatifloxacin ophthalmic solution has been marketed in the US and other countries by Allergan, Inc., a licensing partner of Kyorin.

Gatifloxacin ophthalmic solution has high safety profile as well as superior antibacterial spectrum, and Kyorin expects that this product further contributes to the treatment of more patients in the world including Japan, Asia and the US through our licensing partners.

Under the terms of the License Agreement, Kyorin will receive a lump-sum payment from Senju. Kyorin will supply Senju with gatifloxacin powder, and Senju will manufacture and market the drug product. Kyorin will also receive certain percentages of royalties on local sales in China.

###

Contacts:

Management Planning Department
K Y O R I N C o . , L t d .
T E L : 3 - 3 2 9 3 - 3 4 1 4
F A X : 3 - 3 2 9 3 - 3 4 5 4

About Gatifloxacin Ophthalmic Solution

◆ Japan

Launch: September 2004
Marketed by: Senju Pharmaceutical Co., Ltd.
Brand Name: Gatiflo[®] 0.3% Ophthalmic Solution

◆ US

Launch: April 2003
Marketed by: Allergan, Inc.
Brand Name: Zymar[®]